1. 103083253 对乙酰氨基酚冻干制剂及其制备方法
CN
14.12.2016
A61K 9/19 Loading...
A61K 9/19
Loading...
102011000346693
杭州赛利药物研究所有限公司
范敏华
A61K 9/19
Loading...
本发明涉及对乙酰氨基酚冻干制剂，该冻干制剂由下述物料经冻干得到，包括0.5~5%对乙酰氨基酚、0.5~30%冻干保护剂、0.01~5%螯合剂、0.01‑5% pH调节剂、0.01‑5%抗氧化剂和剩余为溶剂。本发明提供的对乙酰氨基酚冻干制剂及其制备方法，克服了背景技术中对乙酰氨基酚冻干制剂存在稳定下，易受水分、氧气、pH、温度、光照等因素的影响，提供了一种稳定性好、安全性能高的对乙酰氨基酚冻干制剂。
2. 106137977 海参多糖肠溶微丸及其制备方法
CN
23.11.2016
A61K 9/16 Loading...
A61K 9/16
Loading...
102015000204575
浙江普利药业有限公司
范敏华
A61K 9/16
Loading...
本发明涉及一种海参多糖肠溶微丸及其制备方法。该胶囊包括将海参多糖混合制剂辅料加载到丸芯上形成微丸素丸，用隔离层包衣液包裹形成的隔离层和用肠溶层包衣液包裹形成的肠溶包衣层；所述的微丸素丸包括由30%~60%的海参多糖、5%~25%的丸芯、05%~1.5%的交联聚维酮、10%~25%淀粉、1%~5%的聚维酮、10%~30%的95%乙醇、1%~10%的水制备得到。本发明海参多糖肠溶微丸，在胃内不溶出在肠道内快速溶解吸收，避免了海参多糖在胃内被胃酸所降解，影响其生物利用度。
3. WO/2014/127496 PANTOPRAZOLE SODIUM FREEZE-DRY PREPARATION AND PREPARING METHOD THEREOF
WO
28.08.2014
A61K 31/4439 Loading...
A61K 31/4439
Loading...
PCT/CN2013/000434
HAINAN POLY PHARM. CO., LTD.
FAN, Minhua
A61K 31/4439
Loading...
A pantoprazole sodium freeze-dry preparation and a preparing method thereof. The freeze-dry preparation is prepared by dissolving pantoprazole sodium in water for injection, adjusting the PH value to be 9.5 to 11.5 by using a PH regulator, and performing a freeze-dry process. During the preparing process, the water for injection is first cooled, sufficient nitrogen is filled in and a metal chelator is added, then the PH value is regulated, and pantoprazole sodium is added, which fully ensures that the pantoprazole sodium may not be oxidized or degraded during the preparing process and improves temperature stability of the pantoprazole sodium freeze-dry preparation.
4. 103301069 左氧氟沙星颗粒剂及其制备方法
CN
18.09.2013
A61K 9/16 Loading...
A61K 9/16
Loading...
201210067562.9
杭州赛利药物研究所有限公司
范敏华
A61K 9/16
Loading...
本发明涉及左氧氟沙星颗粒剂及其制备方法。左氧氟沙星颗粒剂，至少包括左氧氟沙星含药微丸和掩味缓释包衣层，左氧氟沙星含药微丸包括空白丸芯和左氧氟沙星药物层，空白丸芯和左氧氟沙星药物层的重量比为1:1.5~3；掩味缓释包衣层增重20%~25%，所述的掩味缓释包衣层采用丙烯酸树脂-聚乙二醇溶液进行包衣。本发明左氧氟沙星颗粒掩味效果好，能完全掩盖左氧氟沙星的不良味道，而且本发明还具备缓释功能，能克服左氧氟沙星因为半衰期较短，需要多次服药才能维持有效血药浓度的问题，本发明一天只需服用一次就能维持较长时间的有效血药浓度。
5. 103239406 克拉霉素肠溶制剂及其制备方法
CN
14.08.2013
A61K 9/16 Loading...
A61K 9/16
Loading...
201210021751.2
杭州赛利药物研究所有限公司
范敏华
A61K 9/16
Loading...
本发明涉及克拉霉素肠溶制剂及其制备方法。所述的克拉霉素肠溶制剂，由克拉霉素肠溶包衣颗粒制备得到，所述的克拉霉素肠溶包衣颗粒的粒径在80~45目，包括克拉霉素30%~60%，肠溶材料40%~70%。本发明克拉霉素肠溶制剂，首先将克拉霉素原料和部分肠溶材料混合热熔制粒形成固体分散体，再在制粒后的颗粒外面包肠溶衣，得到的克拉霉素肠溶制剂具备了非常良好的肠溶效果，在胃内几乎不溶出克拉霉素，有效地保证了克拉霉素不会在胃内被降解，而进入肠道后，克拉霉素的分散度较高，会被迅速溶出产生疗效，保证了药物的生物利用度。
6. 103083253 对乙酰氨基酚冻干制剂及其制备方法
CN
08.05.2013
A61K 9/19 Loading...
A61K 9/19
Loading...
201110346693.6
杭州赛利药物研究所有限公司
范敏华
A61K 9/19
Loading...
本发明涉及对乙酰氨基酚冻干制剂，该冻干制剂由下述物料经冻干得到，包括0.5~5%对乙酰氨基酚、0.5~30%冻干保护剂、0.01~5%螯合剂、0.01-5%pH调节剂、0.01-5%抗氧化剂和剩余为溶剂。本发明提供的对乙酰氨基酚冻干制剂及其制备方法，克服了背景技术中对乙酰氨基酚冻干制剂存在稳定下，易受水分、氧气、pH、温度、光照等因素的影响，提供了一种稳定性好、安全性能高的对乙酰氨基酚冻干制剂。
7. 102973579 羟基积雪草苷酸在制备治疗肝纤维化药物中的用途
CN
20.03.2013
A61K 31/7024 Loading...
A61K 31/7024
Loading...
201110263274.6
杭州赛利药物研究所有限公司
范敏华
A61K 31/7024
Loading...
本发明涉及积雪草的用途，尤其涉及积雪草中的单体羟基积雪草苷酸在制备治疗肝纤维化药物中的用途。本发明还提供了治疗肝纤维化的羟基积雪草苷酸注射剂 及其制备方法。本发明有效拓宽了肝纤维化和肝硬化患者的选择，而且和现有的治疗肝纤维化药物比较，本发明具备疗效好、不良副作用小的优点。
8. 102973581 羟基积雪草苷在制备治疗肝纤维化药物中的用途
CN
20.03.2013
A61K 31/7024 Loading...
A61K 31/7024
Loading...
201110263302.4
杭州赛利药物研究所有限公司
范敏华
A61K 31/7024
Loading...
本发明涉及积雪草的用途，尤其涉及积雪草中的单体羟基积雪草苷在制备治疗肝纤维化药物中的用途。本发明还提供了治疗肝纤维化的羟基积雪草苷注射剂 及其制备方法。本发明有效拓宽了肝纤维化和肝硬化患者的选择，而且和现有的治疗肝纤维化药物比较，本发明具备疗效好、不良副作用小的优点。
9. 102973580 积雪草苷酸在制备治疗肝纤维化药物中的用途
CN
20.03.2013
A61K 31/7024 Loading...
A61K 31/7024
Loading...
201110263301.X
杭州赛利药物研究所有限公司
范敏华
A61K 31/7024
Loading...
本发明涉及积雪草的用途，尤其涉及积雪草中的单体积雪草苷酸在制备治疗肝纤维化药物中的用途。本发明还提供了治疗肝纤维化的积雪草苷酸注射剂 及其制备方法。本发明有效拓宽了肝纤维化和肝硬化患者的选择，而且和现有的治疗肝纤维化药物比较，本发明具备疗效好、不良副作用小的优点。
10. 102824302 托吡酯缓释制剂及其制备方法
CN
19.12.2012
A61K 9/00 Loading...
A61K 9/00
Loading...
201110157713.5
杭州赛利药物研究所有限公司
范敏华
A61K 9/00
Loading...
本发明涉及药物缓释制剂，尤其涉及托吡酯缓释制剂及其制备方法。所述的托吡酯缓释制剂由缓释颗粒加制剂辅料制备得到，缓释颗粒包括15-30%托吡酯、30-60%离子交换树脂、12-25%浸渍剂、5-15%缓释包衣材料。本发明提供的托吡酯缓释制剂，具有平稳而有效的血药浓度，低于速释制剂峰浓度，而高于速释制剂峰谷浓度，减少了副反应的发生率，很好的控制癫痫的发作。服药一天一次，同时采用离子交换技术，可以掩盖托吡酯的不良口味，提高了患者的适应性，也将会受到医生和患者的欢迎。
11. 102793684 罗氟司特液体制剂及其制备方法
CN
28.11.2012
A61K 9/48 Loading...
A61K 9/48
Loading...
201110138548.9
杭州赛利药物研究所有限公司
范敏华
A61K 9/48
Loading...
本发明涉及罗氟司特液体制剂。包括药物活性成分、稀释剂和溶剂，所述的药物活性成分为罗氟司特，每1000粒液体制剂中包含罗氟司特0.3~0.8g，稀释剂150g~300g。本发明将罗氟司特制备成液体制剂，解决了罗氟司特在现有制剂中均一性差的问题，提供了一种均一性好的罗氟司特液体制剂。
12. 102579384 Allopurinol slow-release micro pill tablet and preparation method thereof
CN
18.07.2012
A61K 9/26 Loading...
A61K 9/26
Loading...
201110008403.7
杭州赛利药物研究所有限公司
范敏华
A61K 9/26
Loading...
The invention relates to a medicament for treating uarthritis, in particular to an allopurinol slow-release micro pill tablet and a preparation method thereof. The allopurinol slow-release micro pill tablet is prepared by tableting 30-65 percent by weight of allopurinol slow-release pills and 35-70 percent by weight of tablet auxiliary materials, wherein the tablet auxiliary materials include a filling agent; and the allopurinol slow-release micro pills are diaphragm-controlled slow-release micro pills or framework slow-release micro pills. The allopurinol slow-release micro pill tablet disclosed by the invention has the advantages of stable and effective blood concentration, high releasing uniformity, convenience for transporting, and the like.
13. 102475689 混悬分散片及其制备方法
CN
30.05.2012
A61K 9/20 Loading...
A61K 9/20
Loading...
201010573349.6
杭州赛利药物研究所有限公司
范敏华
A61K 9/20
Loading...
本发明涉及药物的剂型，本发明公开一种混悬分散片，至少包括(1)一种有效活性成分；(2)赋形剂混合物，赋形剂混合物至少包括一种崩解剂；(3)混悬颗粒，混悬颗粒包括填充剂、助悬剂、粘合剂。本发明混悬分散片具备了混悬剂在胃肠道分布广、生物利用度高的优点，同时也具备片剂的硬度和易运输和携带以及剂量控制准确的特点。
14. 102462657 马来酸曲美布汀栓剂及其制备方法
CN
23.05.2012
A61K 9/02 Loading...
A61K 9/02
Loading...
201010544972.9
杭州赛利药物研究所有限公司
范敏华
A61K 9/02
Loading...
本发明涉及马来酸曲美布汀栓剂及其制备方法，马来酸曲美布汀栓剂包括栓剂外壳和内容物，内容物以重量百分比计包括2％～10％的马来酸曲美布汀、40％～90％的水溶性基质和5％～15％的保湿剂。本发明马来酸曲美布汀栓剂通过肛门给药的方式，药物活性成分通过直肠下静脉和肛门静脉，经髂内静脉绕过肝进入下腔大静脉，进入大循环，有效地避开了肝首过效应，提高了药物的生物利用度，不用口服避开了患者口服时产生的不良反应，提高患者的顺应性。
15. 102417506 一种抗病毒药物恩替卡韦的制备方法
CN
18.04.2012
C07D 473/18 Loading...
C07D 473/18
Loading...
201010294449.5
杭州赛利药物研究所有限公司
范敏华
C07D 473/18
Loading...
本发明涉及一种抗病毒药物恩替卡韦的制备方法，该方法以D-葡萄糖与丙酮为起始原料，具有易于操作、收率高、分离纯化容易的特点，其原料来源较广，成本较低，从反应一开始就控制了反应的选择性和立体性，能有效抑制手性异构体的产生，产物纯化方法简单且收率较高，关键中间体4-羟甲基-5-亚甲基环戊烷-1，3-二醇，并对其4-羟甲基用三苯基氯甲烷进行选择性保护，经mitsunobu与6氯鸟嘌呤结合，由于空间位阻效应，该保护基不仅能有效保护目标基团，而且在脱除保护基时也易于操作进行。
16. 102397243 马来酸曲美布汀注射剂及其制备方法
CN
04.04.2012
A61K 9/08 Loading...
A61K 9/08
Loading...
201010275788.9
杭州赛利药物研究所有限公司
范敏华
A61K 9/08
Loading...
本发明涉及马来酸曲美布汀注射剂及其制备方法，包括药物活性成分马来酸曲美布汀和附加制剂辅料，其中马来酸曲美布汀的含量为5～20mg/ml，附加制剂辅料为0.1％～2％的止痛剂、0.5％～1.5％的渗透压调节剂，其余为水。本发明所述的马来酸曲美布汀注射剂，起效快，免首过效应，生物利用度高，制备方法简单。
17. 102370629 恩替卡韦液体胶囊及其制备方法
CN
14.03.2012
A61K 9/48 Loading...
A61K 9/48
Loading...
201010253995.4
杭州赛利药物研究所有限公司
范敏华
A61K 9/48
Loading...
本发明涉及治疗乙肝的药物制剂，尤其涉及一种恩替卡韦液体胶囊及其制备方法。恩替卡韦液体胶囊，内容物包括恩替卡韦原料和辅料，内容物包装在硬胶囊壳内，恩替卡韦占内容物的重量百分比为0.02％～2.0％，辅料占内容物种类百分比为98％～99.98％。本发明恩替卡韦液体胶囊解决了背景技术中恩替卡韦低剂量制剂中主药成分的含量均一性问题，以及现有软胶囊存在的制剂工艺复制，胶皮处理与内容物包裹须同时进行；另外软胶囊的水分和氧透过率较高，不利于药物的贮存，胶皮易失水老化，最终产品不易崩解溶出等问题。提供了一种药物均一性好、制剂工艺简单、溶出度高、生物利用度高的恩替卡韦液体胶囊。
18. 102370610 抗过敏药物凝胶剂及其制备方法
CN
14.03.2012
A61K 9/00 Loading...
A61K 9/00
Loading...
201010253991.6
杭州赛利药物研究所有限公司
范敏华
A61K 9/00
Loading...
本发明涉及抗过敏药物凝胶剂及其制备方法。该凝胶剂以地氯雷他定酸性盐为主药，用于治疗皮肤过敏性炎症。本发明公开的抗过敏药物凝胶剂采用了地氯雷他定酸性盐作为主要活性成分，且用β-环糊精，极大的提高了地氯雷他定在水中的溶解性，增强了皮肤透过性，通过透皮吸收，增加机体过敏炎症部位皮肤的局部组织游离药物浓度，可有效拮抗组胺的致敏作用，更好发挥其局部抗过敏和抗炎症疗效，降低不良反应。
19. 102335152 盐酸特比萘芬阴道缓释片及其制备方法
CN
01.02.2012
A61K 9/22 Loading...
A61K 9/22
Loading...
201010231141.6
杭州赛利药物研究所有限公司
范敏华
A61K 9/22
Loading...
本发明涉及盐酸特比萘芬阴道缓释片及其制备方法，所述的阴道缓释片包括盐酸特比萘芬5％～15％、填充剂10％～30％、泡腾剂20％～40％和缓释材料20％～40％。本发明盐酸特比萘芬阴道缓释片，抗菌效果非常好，而且直接针对患处，起效快、生物利用度高，在片剂中添加了泡腾剂和缓释材料，使本发明片剂在能够迅速发挥疗效的同时能维持有效的血药浓度，持续时间比较长。
20. 102335113 克林霉素磷酸酯阴道缓释凝胶及其制备方法
CN
01.02.2012
A61K 9/00 Loading...
A61K 9/00
Loading...
201010231128.0
杭州赛利药物研究所有限公司
范敏华
A61K 9/00
Loading...
本发明涉及克林霉素磷酸酯阴道缓释凝胶及其制备方法。克林霉素磷酸酯阴道缓释缓释凝胶，包括如下重量百分比的组分：克林霉素磷酸酯1％-5％，泊洛沙姆(188)5％-15％，泊洛沙姆(407)8％-20％，羧甲纤维素钠0.5％-2％，卡波姆(980)0.05％-2％，添加剂0.02％-5％，剩余为水。本发明所述到克林霉素磷酸酯阴道缓释凝胶，治疗效果明确、在阴道内滞留时间长、药效持续释放、能长时间起效、患者顺应性好。
21. 102335151 克林霉素磷酸酯阴道黏膜片及其制备方法
CN
01.02.2012
A61K 9/22 Loading...
A61K 9/22
Loading...
201010231118.7
杭州赛利药物研究所有限公司
范敏华
A61K 9/22
Loading...
本发明涉及克林霉素磷酸酯阴道粘膜片及其制备方法。本发明公开的克林霉素磷酸酯阴道黏膜片，包括克林霉素磷酸酯、填充剂、泡腾剂、缓释材料。本发明克林霉素磷酸酯阴道黏膜片，抗菌效果非常好，而且直接针对患处，起效快、生物利用度高，在片剂中添加了泡腾剂和缓释材料，使本发明片剂在能够迅速发挥疗效的同时能维持有效的血药浓度，持续时间比较长。
22. 102283861 Application of magnesium hydrate to pharmacy as well as magnesium hydrate preparation and preparation method thereof
CN
21.12.2011
A61K 33/08 Loading...
A61K 33/08
Loading...
201010202500.5
Hangzhou Saili Pharmaceutical Institute Co., Ltd.
Fan Minhua
A61K 33/08
Loading...
The invention relates to application of magnesium hydrate to pharmacy, which discloses application of the magnesium hydrate to preparation of a medicament for treating constipation in pregnant women. The effective component of the medicament is the magnesium hydrate. The preparation is tablets or turbid liquor. The magnesium hydrate medicinal preparation can be used for treating constipation in pregnant women, thus the constipation in pregnant women can be effectively relieved and treated, the safety is realized and the influence on pregnant women and fetus is avoided; and the magnesium hydrate medicinal preparation has the characteristics of definite curative effect, safety in use and the like.
23. 202036520 药品包装瓶
CN
16.11.2011
A61J 1/00 Loading...
A61J 1/00
Loading...
201120099112.9
杭州赛利药物研究所有限公司
范敏华
A61J 1/00
Loading...
本实用新型涉及药品包装瓶，该包装瓶包括瓶盖和瓶体，瓶盖和瓶体配合连接，其特征在于在瓶盖中设有取药器，取药器穿过瓶盖并固定在瓶盖中。本实用新型解决了背景技术中干混悬剂在取用时存在的剂量不准确和药物易受环境影响的问题，提供了一种使用方便，取用剂量准确的取药装置。
24. 102232929 Voriconazole dried suspension and preparation method thereof
CN
09.11.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
201010164285.4
Hangzhou Sharply Pharm R & D Instit. Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to a Voriconazole dried suspension, comprising 5-15wt% of Voriconazole, 3-20wt% of suspending agent, 30-60wt% of filling agent, 20-50wt% of sweetening agent, 0.1-10wt% of PH regulator, 0.2-2wt% of lubricant, 0.1-2wt% of flavoring agent and 1-5wt% of opacifier. The Voriconazole dried suspension is a fine particle dosage form with more advantages than tablet and other solid dosage forms, has the advantages of large distribution area in gastrointestinal tract, fast absorption and high bioavailability, and can avoid the disadvantage of difficult swallowing of the tablet. Dried suspension is stored as solid, and is given through the mouth in suspension state, so as to be suitable for drugs with low water stability, and for children, the old and the patients who has difficult in swallowing.
25. 102232938 Metaxalone capsule and preparation method thereof
CN
09.11.2011
A61K 9/48 Loading...
A61K 9/48
Loading...
201010164271.2
Hangzhou Sharply Pharm R & D Instit. Co., Ltd.
Fan Minhua
A61K 9/48
Loading...
The invention relates to a metaxalone capsule and a preparation method thereof. The metaxalone capsule content comprises the following components: 20-60% of metaxalone, 20-40% of high molecular material, 5-20% of oil and fat, 10-20% of adsorbent and 0.1-1% of disintegrant. The metaxalone capsule prepared by the invention has the characteristics of high dissolution rate and high bioavailability.
26. 102188389 Trimebutine Maleate suspension and preparation method thereof
CN
21.09.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
201010126925.2
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to a Trimebutine Maleate suspension, which comprises 7 to 25 percent of Trimebutine Maleate particles, 1.5 to 7.5 percent of coating material, 60 to 85 percent of flavoring agent and 3 to 7 percent of suspending aid, wherein the Trimebutine Maleate particles are Trimebutine Maleate crystal particles or medicine particles containing Trimebutine Maleate. The Trimebutine Maleate suspension provided by the invention can effectively hide the unpleasant odor of a Trimebutine Maleate raw material and improve the obedience in patients; and the preparation is highly soluble, can be taken conveniently and helps to solve the difficult swallowing problem of old patients.
27. 102106842 Levofloxacin hydrochloride micropill capsule and preparation method thereof
CN
29.06.2011
A61K 9/52 Loading...
A61K 9/52
Loading...
200910156969.7
Hangzhou Sharply Pharm R & D Instit. Co., Ltd.
Fan Minhua
A61K 9/52
Loading...
The invention relates to a levofloxacin hydrochloride micropill capsule and a preparation method thereof. The levofloxacin hydrochloride micropill capsule comprises a pill core, a medicament-containing layer, a sustained-release coating layer and a quick-release layer, wherein levofloxacin hydrochloride is contained in the medicament-containing layer and the quick-release layer; and the sustained-release coating layer comprises the following materials in percentage by weight: 20 to 60 percent of levofloxacin hydrochloride, 30 to 55 percent of pill core, 10 to 25 percent of binding agent, 3 to 5 percent of sustained-release coating material, 0.3 to 3 percent of pore-forming agent and 0.1 to 1 percent of plasticizer. The levofloxacin hydrochloride micropill capsule has the advantages of high stability, small local stimulation of medicaments, high bioavailability and the like. Due to the adoption of a fluidized bed, the problems of large dust and low yield in a method of powder agglomerating in the background technology are solved.
28. 102106855 Pharmaceutical preparation for resisting tuberculosis and preparation method thereof
CN
29.06.2011
A61K 31/4965 Loading...
A61K 31/4965
Loading...
200910156970.X
Hangzhou Sharply Pharm R & D Instit. Co., Ltd.
Fan Minhua
A61K 31/4965
Loading...
The invention relates to a pharmaceutical preparation for resisting tuberculosis, which comprises rifampin, isoniazid, pyrazinamide and ethambutol hydrochloride, wherein the rifampin or the isoniazid is prepared into micropills and residual materials are prepared into granules. According to the invention, one of the rifampin and the isoniazid is prepared into micropills which are separated by isolation gown and the other one is prepared into granules, so that the rifampin and the isoniazid cannot be mutually influenced, the rifampin is ensured to not be basically degraded in the use process, and the bioavailability of the rifampin is improved.
29. 201882407 一种药品包装盒
CN
29.06.2011
B65D 77/02 Loading...
B65D 77/02
Loading...
201020621179.X
杭州赛利药物研究所有限公司
范敏华
B65D 77/02
Loading...
本实用新型涉及一种药品包装盒，该包装盒包括盒体，在盒体内设有隔板，隔板将盒体分为两个空间，其中一边设有瓶子，另一边设有定量器，瓶子的开口处设有瓶塞，瓶塞上设有通孔。本实用新型解决了药物取用时的不方便以及定量不准确的问题，提供了一种剂量准确，取用方便，尤其是干混悬剂在服用时，先用定量器定量取水，注入瓶子，摇晃震荡使药物混悬成液体，再使用定量器取药服用。
30. 102048677 Valganciclovir Hydrochloride solid preparation and preparation method thereof
CN
11.05.2011
A61K 9/00 Loading...
A61K 9/00
Loading...
200910153793.X
Hangzhou Sharply Pharm R&D Instit. Co., Ltd.
Fan Minhua
A61K 9/00
Loading...
The invention relates to a Valganciclovir Hydrochloride solid preparation and a preparation method thereof. The Valganciclovir Hydrochloride solid preparation comprises (1) Valganciclovir Hydrochloride, (2) polymer material, and (3) preparation auxiliary material. The Valganciclovir Hydrochloride solid preparation has the advantages of high safety, good absorption property, and high bioavailability. Compared with that the conventional Famciclovir adopts intravenous injection mode for use, the invention provides patients with a better choice and avoids safety hazards caused by injection.
31. 102038645 Desloratadine grain and preparation method thereof
CN
04.05.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
200910153417.0
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to a desloratadine grain and a preparation method thereof. The preparation method comprises the steps: fully coating a medicine and proper auxiliary materials (such as a stabilizing agent, a cosolvent, a PH adjusting agent, a filling agent and the like) into a water-soluble high molecular material; and adding a proper opacifier into a coating material, so that the medicine can be isolated from the light and the external moist air when the medicine is stored, and the stability of the medicine can be adequately guaranteed when the medicine is stored under the room temperature; mixing the coated grain with a proper flavoring agent and soluble auxiliary materials to obtain the desloratadine granular formulation; and properly adding a small quantity of edible coloring agent and fruity essence to increase the novelty to the children, and improve the taking compliance.
32. 102038691 Composite preparation of vitamins and amino acids and preparation method thereof
CN
04.05.2011
A61K 31/592 Loading...
A61K 31/592
Loading...
200910153422.1
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 31/592
Loading...
The invention relates to a composite preparation of vitamins and amino acids. A micro pill is prepared by sequentially coating various vitamins and various amino acids. The obtained composite preparation of vitamins and amino acids combines various vitamins and amino acids, and is convenient to use. With the adoption of the slow release coating technology in the micro pill, the bioavailability is improved, the quality is stable, and the human body quickly absorbs the composite preparation.
33. 102038662 Nifedipine controlled release micro-pill preparation and preparation method thereof
CN
04.05.2011
A61K 9/26 Loading...
A61K 9/26
Loading...
200910153424.0
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/26
Loading...
The invention relates to a nifedipine controlled release micro-pill preparation and a preparation method thereof. The nifedipine controlled release micro-pill preparation comprises 30% to 70% of nifedipine, 10% to 30% of empty pill core, 1% to 5% of adhesive, 15% to 40% of controlled release material and 3% to 10% of anti-sticking agent. The preparation method comprises the steps that medical active components cover the surface of the empty pill core and then are covered with the controlled release coating to prepare a nifedipine controlled release micro-pill; and finally, the capsule is filled to prepare a nifedipine controlled release capsule or the controlled release micro-pill and a filling agent are mixed and tableted to prepare nifedipine controlled release tablets. The nifedipine controlled release micro-pill preparation has the advantages of complete controlled release and stable effect, and is suitable for mass production.
34. 102038619 Bathing particles and preparation method thereof
CN
04.05.2011
A61K 8/97 Loading...
A61K 8/97
Loading...
200910153423.6
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 8/97
Loading...
The invention relates to bathing particles and a preparation method thereof. The bathing particles comprise coffee and ginger extracts. The bathing particles are thrown into a bathing container before a bath and dissolved to release heating components and slimming components for activating blood circulation of skin, extending pores and promoting absorption of effective components. The bathing particles have functions of sweating, making the body fragrant, warming the body, emitting pleasant smell, calming, soothing the nerves and pleasing people as well as the advantages of high effectiveness, safety, no allergy and no stimulation.
35. 101991543 Omeprazole enteric dried suspension agent and preparation method thereof
CN
30.03.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
200910100955.3
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to an omeprazole enteric dried suspension agent and a preparation method thereof. The omeprazole enteric dried suspension agent comprises 5 to 20 weight percent of omeprazole pellet or granule, 1 to 10 weight percent of suspending agent and 70 to 90 weight percent of flavoring agent. The omeprazole enteric dried suspension agent has stable quality, quick response and good suspension effect and it is convenient for old people, children and dysphagia patients to use the suspension agent.
36. 101991574 Desloratadine external preparation and preparation method thereof
CN
30.03.2011
A61K 31/4545 Loading...
A61K 31/4545
Loading...
200910102029.X
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 31/4545
Loading...
The invention relates to a desloratadine external preparation and a preparation method thereof. The external preparation takes desloratadine as a main drug and is used for treating allergic skin inflammation. The desloratadine external preparation can increase the concentration of free drug in skin local tissues of the part with the allergic skin inflammation of a body through percutaneous absorption, have an effective histamine sensitization antagonism role, better play local antianaphylaxis and anti-inflammation efficacies and reduce adverse reactions. The external formulation does not pass through the gastrointestinal tract, thereby avoiding the first pass effect and reduce the probability of occurrence of adverse reactions. The external preparation can be directly applied at the affected side, and the onset of action is rapid. Furthermore, the dose and the coverage area of the external preparation can be selected according to the area and the severity of the affected site, and the external preparation is convenient to use and convenient to carry.
37. 101991558 Diclofenac potassium liquid capsule and preparation method thereof
CN
30.03.2011
A61K 9/48 Loading...
A61K 9/48
Loading...
200910102032.1
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/48
Loading...
The invention relates to a diclofenac potassium liquid capsule and a preparation method thereof. The diclofenac potassium liquid capsule comprises a capsule casing and a content, wherein the content comprises 5-25 percent of diclofenac potassium, 0.5-40 percent of surface active agent, 0.5-40 percent of sorbefacient and 0.1-30 percent of melting point regulating agent in percent by weight. The diclofenac potassium liquid capsule is rapid in taking effect and stable in absorption, is taken after the meal, has the effect equal to the suppository or the administration with an empty belly, and provides a better medication preparation selection for a patient.
38. 101991544 Azithromycin enteric dry suspension and preparation method thereof
CN
30.03.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
200910100956.8
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to an azithromycin enteric dry suspension and a preparation method thereof. The dry suspension comprises the following components in percentage by weight: 4 to 10 percent of azithromycin, 0.3 to 0.5 percent of isolated coating material, 1.6 to 3.2 percent of enteric coating material, 75 to 90 percent of flavoring agent and 3 to 6 percent of suspending agent. The azithromycin enteric dry suspension solves the problem that the azithromycin stimulates gastric mucosa in the background art, and provides an azithromycin preparation which is dissolved, released and absorbed in intestinal tracks. The azithromycin enteric dry suspension also solves the problem that the basic remedy and a capsule shell in an azithromycin enteric capsule generate cross-linking reaction, and masks the bitterness of the azithromycin through a taste masking technique, so the azithromycin enteric dry suspension is suitable for medicaments for children.
39. 101991557 Liquid vancomycin hydrochloride capsule and preparation method thereof
CN
30.03.2011
A61K 9/48 Loading...
A61K 9/48
Loading...
200910100952.X
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/48
Loading...
The invention relates to vancomycin hydrochloride and a preparation method thereof. A liquid vancomycin hydrochloride capsule comprises a capsule shell and a content, wherein the content comprises 10-50 percent of the vancomycin hydrochloride, 20-50 percent of diluent, and 20-50 percent of solvent. The invention benefits to solving the problem that vancomycin hydrochloride injections in the prior art have huge side effect, and provides the liquid vancomycin hydrochloride capsule which has the advantages of quick effect-taking performance, low side effect, and attractive appearance and is convenience for use and carrying.
40. 101991528 Diclofenac potassium dry suspension and preparation method thereof
CN
30.03.2011
A61K 9/00 Loading...
A61K 9/00
Loading...
200910102030.2
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/00
Loading...
The invention relates to a diclofenac potassium dry suspension and a preparation method thereof. The diclofenac potassium dry suspension comprises 1.0%-3.0% of main medicine diclofenac potassium, 0.2%-1% of high molecular material, 0.5%-2% of suspending agent, 70%-92% of filler and 3%-15% of flavoring agent. Since the diclofenac potassium has poor taste, which possibly causes poor administration compliance, raw materials are coated with a proper high molecular material firstly, and under the condition of not influencing the release of the medicine, the main medicine is coated in the high molecular material completely to separate the medicine from taste buds to isolate bad flavor; in addition, the proper suspending agent, the flavoring agent, the filler and a lubricant are matched to finally obtain the dry suspension. The diclofenac potassium dry suspension obtained by the invention has good administration compliance and achieves the advantages of fast effect taking, good analgesic effect, stable absorption, high biological availability and the like in comparison with diclofenac sodium.
41. 101991619 Pomegranate controlled-release pellets and preparation method thereof
CN
30.03.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
200910100953.4
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to pomegranate controlled-release pellets and a preparation method thereof. The pellets are prepared from 20-50wt% of main drug of pomegranate extract, 20-50wt% of pellet core and 0.5-3wt% of bonding agent. The invention solves the problem that a pomegranate preparation in the background technology has low bioavailability because the pomegranate preparation cannot maintain stable plasma concentration, and provides the pomegranate controlled-release pellets with high bioavailability.
42. 101991542 Lansoprazole enteric dry suspension and preparation method thereof
CN
30.03.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
200910100954.9
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to lansoprazole enteric dry suspension and a preparation method thereof. The lansoprazole enteric dry suspension comprises the following components in percentage by weight: 15 percent-50 percent of lansoprazole pellets or particles, 1 percent-10 percent of suspending agents and 50 percent-85 percent of flavoring agents. The prepared lansoprazole enteric dry suspension has the advantages of stable quality, quick response, good suspension effect and high biological utilization degree, and is convenient for old people, children and patients suffered from dysphagia.
43. 101991545 Caffeine slow-release micro pill preparation and preparation method thereof
CN
30.03.2011
A61K 9/16 Loading...
A61K 9/16
Loading...
200910102031.7
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to a caffeine slow-release micro pill preparation, which comprises the following components in percentage by weight: 50-80% of caffeine, 15-30% of empty pill core, 1-4% of binder, 10-20% of slow-release material and 5-20% of antiadherent. By taking the caffeine slow-release micro pill preparation once a day, effective blood concentration can be maintained for 8-10 hours. The effective blood concentration is achieved after taking the preparation for 1-2 hours in the morning so as to excite pallium, improve awareness of people and maintain good compliance of a patient for 8-10 hours. The blood concentration in the evening is lower than the effective dosage and does not affect sleep.
44. 101991540 Ibuprofen injection and preparation method thereof
CN
30.03.2011
A61K 9/14 Loading...
A61K 9/14
Loading...
200910102028.5
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/14
Loading...
The invention relates to ibuprofen injection and a preparation method thereof. The ibuprofen injection comprises 0.5 to 20 weight percent of ibuprofen, 10 to 60 weight percent of cyclodextrin or cyclodextrin derivatives, 1 to 40 weight percent of water soluble excipient and the balance of water, wherein ibuprofen serves as a main medicament; and the cyclodextrin or cyclodextrin derivatives and the water soluble excipient serve as medicinal auxiliary materials. In the invention, the cyclodextrin or cyclodextrin derivatives represented by hydroxypropyl-beta-cyclodextrin is used to make the ibuprofen, which used to be water insoluble, very water soluble. The stability of the medicament is improved. The clathrate compounds can be made into injection using water as a solvent or power for injection. Thus, it is very convenient to administrate the medicament in clinic and it is easy to control injection volume. Meanwhile, the drawback of the universal adoption of auxiliary materials and solvents for injection, which are very dangerous, such as organic solvents and cosolvents, of the conventional insoluble and soluble medicinal injection is overcome.
45. 101935310 Refining process of famotidine raw material
CN
05.01.2011
C07D 277/42 Loading...
C07D 277/42
Loading...
200910097581.4
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
C07D 277/42
Loading...
The invention relates to a refining process of a famotidine raw material. The refining process of the famotidine raw material adopts the method of dimethylformamide and purified water for refining. The refining process can effectively reduce the content of impurities in the famotidine raw material, reduce the content of the impurities to below 0.1%, and further control the incidence of adverse reactions from a source of the raw material; furthermore, the process can lead the yield of famotidine to be high and is simple to operate.
46. 101933914 Desloratadine patch and preparation method thereof
CN
05.01.2011
A61K 9/70 Loading...
A61K 9/70
Loading...
200910100104.9
Hangzhou Sharply Pharmaceutical Research and Development Institute Co., Ltd.
Fan Minhua
A61K 9/70
Loading...
The invention relates to a desloratadine patch and a preparation method thereof. The desloratadine patch comprises a patch film and medicament components on the patch film, wherein the medicament components comprise main component desloratadine and auxiliary materials; and the auxiliary materials comprise a solubilizing agent, a substrate, a cross-linking agent, an excipient and an osmosis reinforcing agent. The invention overcomes the bias that in the prior art, the desloratadine is considered to be difficult to externally penetrate through the skin cuticle and not to reach effective tissue concentration in the skin tissue so as not to exert the curative effects of allergic resistance and inflammation resistance, solves the problem of poor solubility of the desloratadine, improves the permeability of the desloratadine on the skin cuticle, ensures that the desloratadine rapidly arrives at the affected part and takes the effect rapidly and solves the problems of inconspicuous effect-taking and obvious first pass effect on gastrointestinal tract of the traditional patch. The desloratadine patch has the advantages of good curative effect, rapid action, less toxic or side effect and convenient use.
47. 101804145 Garlic oil enteric pellet capsule and preparation method thereof
CN
18.08.2010
A61K 9/48 Loading...
A61K 9/48
Loading...
200910095835.9
Hainan Poly Pharm Co., Ltd.
Fan Minhua
A61K 9/48
Loading...
The invention relates to the field of antibacterial agent, in particular to a garlic oil enteric pellet capsule and a preparation method thereof. Wherein the garlic oil pellet capsule is composed of a coated pellets and a coating layer, the coated pellets comprises pharmaceutically active ingredients of garlic oil and coated pellet minor ingredient; wherein the coated pellet minor ingredient comprises pellet core, bonding agent, absorbing agent, disintegrating agent, antioxygen agent and antiplastering aid while the coating layer comprises an enteric coating and an isolated layer; the coated pellet comprises the following components according to weight percentage: 5-40% of garlic oil, 10-60% of pellet core, 2-10% of binding agent, 20-50% of absorbing agent, 0.5-5% of antioxygen agent, 0.5-10% of disintegrating agent and 2-20% of antiplastering aid.Compared with the existing allicin dosage form, the garlic oil enteric pellet capsule of the invention enjoys more advanced dosage form, thus ensuring effectiveness and stability of the capsule and high bioavailability; in addition, with the enteric pellet capsule of the invention, harm done to gastric mucosa as the capsule is dissolved inside the stomach is avoided and the allicin is not damaged by gastric acid so that drug effect of the capsule is not affected.
48. 101804030 Sodium dichlorophenolate micro-pill pharmaceutical preparation and preparation method thereof
CN
18.08.2010
A61K 9/16 Loading...
A61K 9/16
Loading...
200910095834.4
Hainan Poly Pharm Co., Ltd.
Fan Minhua
A61K 9/16
Loading...
The invention relates to the pharmaceutical preparation field and in particular to a sodium dichlorophenolate micro-pill pharmaceutical preparation and a preparation method thereof. The micro-pill pharmaceutical preparation is prepared by micro-pills, which is characterized in that the micro-pill is of enteric slow-release micro-pill, the micro-pill consists of a hollow pill core, an active layer and an outer layer lagging cover, the active layer comprises sodium dichlorophenolate, a binding-property slow-release material and a binding-property enteric material, and the outer layer comprises a slow-release material. With the particular process and formula, a release system thereof is made into a unique double slow-release system, i.e. a skeleton-type scattering system is combined with a multi-layer semi-penetration film lagging cover system, so the main medicine can be continuously and stably released in the complicated internal environment of the human body. In addition, by adopting unique auxiliary materials, the micro-pill is free from being dissolved in the stomach and almost has no harm on the gastric mucosa, the medicine is ensured to have continuous effect of 24 hours inside the intestinal tract, the bioavailability is improved, and the application effect of the medicine is ensured.
49. 201404471 一种老化锅
CN
17.02.2010
A61J 3/00 Loading...
A61J 3/00
Loading...
200920113742.X
杭州赛利药物研究所有限公司
范敏华
A61J 3/00
Loading...
本实用新型涉及制药设备领域，尤其涉及一种老化锅，本实用新型老化锅，包括外壳、包衣锅，外壳内还设置进风管，进风管一端设置在外壳上，另一端设置包衣锅上方，进风管位于外壳的一端上设置有除湿器，进风管上还设有热风加热器，外壳上还设有出风口。本实用新型一种老化锅，能够使药品制剂的包衣层在一个相对恒温、恒湿的环境内进行老化，进一步稳固包衣层，本实用新型老化锅的进风温度范围大、温度、湿度可控，包衣锅的转速可控，而且结构简单实用。
50. 1507868 Desloratadine dry-mixed suspensoid and preparing method thereof
CN
30.06.2004
A61K 31/4545 Loading...
A61K 31/4545
Loading...
02148577.1
Puli Pharmaceutical Co., Ltd., Hainan
Fan Minhua
A61K 31/4545
Loading...
The present invention discloses a new dosage form of dichloroleitadine. It includes coated dichloroleitadine, and its content is 0.01-1%, and its coating material is methyl aminoalkyl acrylate copolymer type E and II acrylic resin. The dichloroleitadine raw material is sensitive to light heat and humidity, in order to ensure its stability, said raw material is coated so as to improve its non-stability, at the same time can hide its taste.
51. 1507861 Trimebutine maleate tablet and preparing method thereof
CN
30.06.2004
A61K 31/235 Loading...
A61K 31/235
Loading...
02148576.3
Puli Pharmaceutical Co., Ltd., Hainan
Fan Minhua
A61K 31/235
Loading...
The present invention relates to a kind of oral trimebutine tablet and its preparation method. Said invention is characterized by that the trimebutine raw material can be coated with water soluble film-forming agent and plasticizer. The tablet made up by said method can hide the taste of trimebutine, at the same time it does not affect disintegration and does not affect resolution of its main component.
52. 1432366 Use of mica in preparing medicine
CN
30.07.2003
A61K 33/06 Loading...
A61K 33/06
Loading...
02110568.5
Hainan Pulin Pharmaceutical Co., Ltd.
Yao Jianmin
A61K 33/06
Loading...
The present invention relates to a new use of mica in preparing medicine for atrophic gastritis. By means of duplication of rat model of chronic atrophic gastritis, are observed the morphopathological, nuclear proliferation antigen and epidermal growth factor effects of mica and its positive reference medicine sucralfate. The results show that mica can reduce gastric mucosa inflammation cell infiltration and glandulose atrophy, increase the positive expression of glandulose nuclear proliferation antigen and raise the expression level of blood serum epidermal growth factor. That is to say, mica has relatively high rat chronic atrophic gastritis treating effect and certain chronic atrophic gastritis preventing and treating effect.
53. 1432362 Oral Nimoldipine prepn and its prepn process
CN
30.07.2003
A61P 9/10 Loading...
A61P 9/10
Loading...
02110531.6
Hangzhou Saili Medicine Inst. Co., Ltd.
Fan Minhua
A61P 9/10
Loading...
The preparation process of oral Nimoldipine preparation includes the technological steps of: adding polymer carrier hydroxyproply methyl cellulose, polysorbate-80, absorption promoter sodium dodecyl sulfate into ethanol; heating to become transparent; adding low smelting point Nimoldipine while stirring until becoming transparent; quick freezing at -35 to -25 deg.c; adding absorption promoter oleic acid, avical and carboxy methyl amylose sodium to prepare soft material; pelletizing with 18-mesh nylon sieve; drying at 40-50 deg.c; finishing and capsulizing. The Nimoldpine capsule has biological utilization of 94.82% of that of Nimoldipine.
54. 1429553 Use of centella total glycoside in manufacture of medicine
CN
16.07.2003
A61K 31/56 Loading...
A61K 31/56
Loading...
01145321.4
Hangzhou Saili Pharmaceuticals Inst. Co., Ltd.
Hu Gang
A61K 31/56
Loading...
A novel application of centella asiatica to preventing and treating mastoplasia is disclosed.

